Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and
Veradermics' hair loss medicine worked really well in its big test. The drug helped people grow more hair and was safe to use.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.